Table 1.
Distribution of antimicrobial resistance prevalences in study isolates by gender, ST69 and ST 73
| Antimicrobial | Number and (%) of resistant antimicrobial isolates | Number and (%) in ST | |||
|---|---|---|---|---|---|
|
| |||||
| Total N=139 | Women N=127 | Men N=12 | ST69 N=15 | ST73 N=21 | |
| Amikacin | 3 (2) | 3 (2) | 0 | 0 | 1 (5) |
| Amoxicillin-clavulanic acid | 28 (20) | 24 (19) | 4 (33) | 3 (20) | 6 (29) |
| Ampicillin | 101 (73) | 91 (72) | 10 (83) | 14 (93) | 14 (67) |
| Cefotaxime | 4 (3) | 2 (1.5) | 2 (17) | 0 | 0 |
| Cefoxitin | 12 (9) | 10 (0.8) | 2 (17) | 2 (13) | 0 |
| Ceftazidime | 1 (0.7) | 0 | 1 (8) | 0 | 0 |
| Cefuroxime | 8 (6) | 6 (5) | 2 (17) | 2 (13) | 0 |
| Cephalothin | 107 (77) | 98 (77) | 9 (75) | 14 (93) | 17 (81) |
| Ciprofloxacin | 9 (7) | 8 (6) | 1 (8) | 0 | 0 |
| Fosfomycin | 4 (3) | 4 (3) | 0 | 1(7) | 0 |
| Gentamicin | 3 (2) | 3 (2) | 0 | 0 | 0 |
| Imipenem | 0 | 0 | 0 | 0 | 0 |
| Levofloxacin | 9 (7) | 8 (6) | 1(8) | 0 | 0 |
| Meropenem | 0 | 0 | 0 | 0 | 0 |
| Nalidixic acid | 14 (10) | 13 (10) | 1 (8) | 1 (7) | 0 |
| Nitrofurantoin | 4 (3) | 4 (3) | 0 | 0 | 0 |
| Norfloxacin | 9 (7) | 8 (6) | 1(8) | 0 | 0 |
| Trimethoprim/Sulfamethoxazole | 63 (45) | 59 (46) | 4 (33) | 14 (93) | 2 (10)a |
a
p <0.001 for comparison with ST69. All other comparisons are p >0.05.